

Supplemental Table 2. Clinical parameters at the time of liver biopsies (Case 5, 6, and 7)

	Case 5 (male, 60 years at 1st biopsy)			Case 6 (male, 53 years at 1st biopsy)			Case 7 (male, 55 years at 1st biopsy)			1st vs. 2nd <i>P</i> **	2nd vs. 3rd <i>P</i> **	1st vs. 3rd <i>P</i> **
	1st biopsy* (At pretreatment)	2nd biopsy* (At 24 weeks)	3rd biopsy (At 3.5 years)	1st biopsy* (At pretreatment)	2nd biopsy* (At 24 weeks)	3rd biopsy (At 1.7 years)	1st biopsy* (At pretreatment)	2nd biopsy* (At 24 weeks)	3rd biopsy (At 3.5 years)			
Physical examination												
Body mass index (kg/m ²)	29.0	27.4	29.2	36.9	34.2	36.5	31.1	28.9	29.5	0.018	0.018	0.063
Waist circumference (cm)	102.3	98.5	106.3	121.3	115.6	118.5	94.2	90.3	90.6	0.018	0.018	0.612
Comorbidities												
Hypertention (Treatment)	Yes (ARB, CCB)	Yes (ARB, CCB)	Yes (ARB, CCB)	Yes (ARB, CCB)	Yes (ARB, CCB)	Yes (ARB, CCB)	Yes (ARB, CCB)	Yes (CCB)	Yes (CCB)			
Dyslipidaemia (Treatment)	Yes (HMG-CoA reductase inhibitor)	Yes (HMG-CoA reductase inhibitor)	Yes (HMG-CoA reductase inhibitor)	Yes (ω-3 carboxylic acids)	Yes (ω-3 carboxylic acids)	Yes (ω-3 carboxylic acids)	No	No	No			
Antidiabetic agents, expect for SGLT2 inhibitor	Yes (DPP-4 inhibitor, Metformin)	Yes (DPP-4 inhibitor, Metformin)	Yes (DPP-4 inhibitor, Metformin)	Yes (DPP-4 inhibitor, Metformin)	Yes (DPP-4 inhibitor, Metformin)	Yes (DPP-4 inhibitor, Metformin)	Yes (Metformin)	Yes (Metformin)	Yes (Metformin)			

		Metformin)	Sulfonylure a)		Metformin n)	Metformin n)							
Laboratory data													
Serum aspartate aminotransferase (U/L)	32	23	66	174	67	90	53	27	26	0.028	0.344	0.352	
Serum alanine aminotransferase (U/L)	50	29	88	294	127	149	83	41	45	0.046	0.173	0.271	
Alkaline phosphatase (U/L)	191	165	212	205	141	169	171	237	206	0.398	0.063	0.398	
Gamma-glutamyl transpeptidase (U/L)	46	22	55	118	73	82	42	59	46	0.128	0.237	0.612	
Estimate glomerular filtration rate (ml/min/1.73m ³)	102.9	89.9	77.5	79.2	71.4	71.9	62.8	57.0	61.8	0.043	0.735	0.063	
Fasting plasma glucose (mg/dL)	134	119	133	156	119	136	133	108	125	0.018	0.018	0.176	
C-peptide (ng/mL)	3.79	3.31	3.58	4.38	3.44	3.78	2.18	3.46	3.36	0.128	0.398	0.237	
HbA1c (%)	7.3	6.7	7.9	8.6	6.7	7.0	6.5	6.2	7.3	0.04	0.01	0.61	

										3	8	1
HOMA-IR	5.0	2.9	3.3	8.2	6.4	8.0	6.8	5.2	5.5	0.02	0.75	0.02
										8	2	8
HOMA-β (%)	90	92	68	90	144	120	84	122	64	0.46	0.02	0.24
										2	8	9
Total cholesterol (mg/dL)	144	152	145	168	172	179	157	139	154	0.86	0.44	0.75
										6	6	3
Triglycerides (mg/dL)	256	208	191	128	139	145	219	139	174	0.31	0.39	0.55
										0	8	3
High-density lipoprotein cholesterol (mg/dL)	57	56	47	46	47	46	35	34	37	0.38	0.49	0.52
										0	9	8
Low-density lipoprotein cholesterol (mg/dL)	52	59	74	98	106	115	72	68	90	0.86	0.23	0.35
										6	7	2
Uric acid (mg/dL)	6.4	6.3	6.6	3.9	4.1	3.6	6.9	5.1	4.9	0.23	0.04	0.02
										7	2	8
Hyaluronic acid (μg/L)	18	23	53	130	94	97	13	20	12	0.17	0.04	0.91
										6	2	6
Type IV collagen 7S (ng/mL)	21.2	18.6	25.8	9.6	7	9.0	4.1	3.0	3.7	0.01	0.02	0.79
										8	8	9
Procollagen III peptide (U/mL)	1.10	1.30	1.90	1.20	0.90	1.00	1.00	0.70	0.60	0.89	1.00	1.00
										1	0	0
High sensitive C-reactive	0.020	0.015	0.012	0.163	0.043	0.062	0.050	0.137	0.200	0.75	0.73	0.73
										3	5	5

protein (mg/dL)													
Serum ferritin (µg/L)	1696	410	958	466	83	95	204	119	193	0.018	0.310	0.018	
Fibrosis-4 index	1.14	1.19	1.97	3.38	1.90	2.69	2.42	2.13	1.12	0.237	0.612	0.398	
Imaging													
Liver stiffness measurement with transient elastography (kPa)	5.2	3.2	7.0	27.0	16.9	15.1	9.4	5.9	7.9	0.018	0.176	0.237	
Liver fat with magnetic resonance spectroscopy (%)	17.6	11.5	22.9	14.0	7.0	11.4	27.0	12.2	20.8	0.018	0.128	0.237	

*Results of 1st and 2nd liver biopsies, are based on the previous prospective study (Reference 8,9).

**Wilcoxon test was used for comparison of paired samples of 7 patients.

ARB; Angiotensin II receptor blocker, CCB; Calcium channel blocker, DPP-4; dipeptidyl-peptidase 4, HMG-CoA; 3-hydroxy-3-methylglutaryl-coenzyme A.